ProPhase Labs Acquires Nebula Genomics
August 11, 2021
ProPhase Labs, through its newly formed subsidiary ProPhase Precision Medicine, completed the acquisition of Nebula Genomics, a privately owned whole‑genome sequencing and personal genomics company. The deal (approximately $14.6 million in a mix of cash and ProPhase common stock) will integrate Nebula’s whole genome sequencing capabilities and DTC platform into ProPhase’s CLIA-certified molecular testing laboratories to expand diagnostic and consumer genomics offerings.
- Buyers
- ProPhase Labs, Inc., ProPhase Precision Medicine, Inc.
- Targets
- Nebula Genomics
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Swiss Rockets AG to Acquire Complete Genomics
February 23, 2026
Healthcare Services
Complete Genomics entered into a definitive agreement to be acquired by Swiss Rockets AG, subject to customary closing conditions and approval by MGI shareholders. Swiss Rockets will own 100% of Complete Genomics and have sole control, while Complete Genomics continues operating as a U.S.-based company with its management team retaining responsibility for day-to-day operations and customer relationships.
-
PrimeGen US Enters Definitive Business Combination With DT Cloud Star Acquisition Corporation
February 4, 2026
Biotechnology
PrimeGen US, Inc. entered into a definitive business combination agreement with DT Cloud Star Acquisition Corporation (a publicly traded SPAC), implying an equity value of approximately $1.5 billion. The transaction is expected to provide access to public markets capital to advance PrimeGen US’s stem cell and exosome therapies, with an anticipated closing in the second half of 2026 subject to approvals and customary closing conditions.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp has completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a cancer genomics company focused on liquid biopsy and tissue-based genomic products and services. The deal builds on and expands Labcorp’s oncology and next-generation sequencing (NGS) capabilities and liquid biopsy offerings.
-
Tesis Biosciences Acquires Genome Explorations
February 16, 2022
Biotechnology
Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.
-
Mesa Laboratories Acquires Agena Bioscience
September 14, 2021
Medical Devices
Mesa Laboratories, Inc. (NASDAQ:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. for $300 million in cash. Agena, a San Diego–based molecular diagnostics and genomics tools company, is expected to add roughly $63–67 million of revenue (about 65% recurring) in the first 12 months and will form Mesa’s new Clinical Genomics Division.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.